• Sodium Oxamate: From Flux Block to Causal Biology

  2026-08-20

  Sodium Oxamate is more than an LDH-A inhibitor: it can help connect lactate production with chromatin state and cancer-cell fate. This article presents a causal assay framework grounded in recent triple-negative breast cancer research.

• Reelin Signaling Permits Ketamine Synaptic Action

  2026-08-20

  This PNAS study identifies Reelin–Apoer2–Src family kinase signaling as a permissive pathway for ketamine-induced hippocampal synaptic plasticity and behavioral effects in mice. Its central contribution is the distinction between pathway activation by ketamine and maintenance of baseline NMDA receptor function, offering a mechanistic framework for understanding incomplete ketamine responsiveness.

• Blue Light, EGFR/ERK/c-Jun, and Skin Barrier Damage

  2026-08-19

  The reference study establishes a human- and mouse-based framework showing that repeated blue light exposure produces persistent structural, pigmentary, and functional skin-barrier abnormalities. Its mechanistic contribution is the identification of EGFR/ERK/c-Jun signaling as a pathway linking visible-light irradiation to epidermal stress and barrier dysfunction.

• Triamcinolone: Practical Research Workflow Guide

  2026-08-19

  Triamcinolone is a synthetic glucocorticoid agonist for controlled studies of glucocorticoid signaling, inflammation, and immunosuppression. This guide addresses solubilization, storage, assay setup, and quality control, while emphasizing that the product is for scientific research only and not for diagnostic or clinical use.

• 3-Methyladenine as a Vacuole–Autophagy Probe

  2026-08-18

  Explore how 3-Methyladenine and 3-MA can separate autophagy inhibition from pathogen-induced vacuolization and macrophage death. This practical framework connects PI3K signaling, floatptosis, and assay design without overinterpreting a single inhibitor.

• Palomid 529: A Smarter ESCC Assay Strategy

  2026-08-18

  Palomid 529 (P529) offers a practical way to interrogate dual mTORC1/mTORC2 control downstream of the RCN2–PPP2CA–PI3K-AKT axis. This article presents an assay-centered framework for studying ESCC resistance, angiogenesis, and radiotherapy enhancement without overstating pathway evidence.

• LDN-193189: BMP Signaling Workflow Guide

  2026-08-17

  LDN-193189 is a selective ALK inhibitor for dissecting BMP-driven Smad and non-Smad signaling in cell, epithelial, and exploratory neurobiology workflows. This practical guide connects validated BMP assays with the scalable human sensory-neuron model reported for HSV-1 latency research, while clearly separating established uses from emerging applications.

• Anlotinib and Multitarget Angiogenesis Inhibition

  2026-08-17

  The reference study shows that anlotinib suppresses angiogenesis by inhibiting VEGFR2, PDGFRβ, and FGFR1 activation together with downstream ERK signaling. Its combination of endothelial-cell assays, vascular sprouting models, and comparator TKIs provides a useful preclinical framework for studying multi-pathway angiogenesis inhibition.

• 25-Hydroxycholesterol Reprograms TAM Immunity

  2026-08-16

  Xiao et al. identify CH25H and lysosomal 25-hydroxycholesterol as an immunometabolic checkpoint that activates AMPKα and reinforces STAT6-dependent ARG1 production in tumor-associated macrophages. The study connects cholesterol handling to macrophage education, T-cell exclusion, and anti-PD-1 response, providing a mechanistic framework for investigating metabolic control of tumor immunity.

• NSC-23766: From Rac1 Mechanism to Translation

  2026-08-15

  NSC-23766 trihydrochloride offers translational researchers a mechanistically defined way to interrogate Rac1 activation, connecting GEF-dependent signaling with endothelial barrier integrity, survival, migration, stemness, and breast cancer biology. This article positions the compound as a research tool for disciplined pathway validation rather than as a standalone therapeutic, with practical guidance on controls, assay design, combination studies, and interpretation of translational evidence.

• Netarsudil and Predictive siRNA Codelivery

  2026-08-14

  Slaughter et al. developed a quantitative framework for predicting whether ionizable drugs can complex siRNA and become functional components of ionizable drug nanoparticles. Netarsudil (AR-13324) emerged as a high-performing candidate and, in fibrotic human trabecular meshwork cells, supported CTGF mRNA reduction alongside decreased actin network density.

• Imatinib in Gastric Cancer Assembloid Research

  2026-08-14

  Imatinib (STI571) can serve as a mechanistic probe for testing how patient-matched gastric tumor stroma reshapes tyrosine kinase dependency, drug response, and translational decision-making.

• MK 0893 Glucagon Receptor Antagonist Workflows

  2026-08-13

  Build more informative GCGR experiments by pairing receptor-binding measurements with functional cAMP assays and glucose-challenge models. MK 0893 offers a practical benchmark for connecting allosteric receptor pharmacology to translational type 2 diabetes research while preserving attention to solubility, selectivity, and assay controls.

• Radicicol: Hsp90 Inhibitor Assay Workflows

  2026-08-13

  Radicicol is a versatile Hsp90 inhibitor for adipogenesis, apoptosis, kinase, and inflammation studies. This practical guide connects target-selective assay design with the LKB1-AMPK mitochondrial framework reported in periodontal stem-cell research, while separating established evidence from exploratory workflows.

• Rapamycin (Sirolimus) Cell Assay Workflows

  2026-08-12

  A scenario-based guide to using Rapamycin (Sirolimus), SKU A8167, in viability, proliferation, and cytotoxicity experiments. It covers dose selection, solvent controls, pathway interpretation, autophagy-related confounding, and practical product-selection criteria.

16436 records 1/1096 page Next 12345 下5页 Last page